Ultragenyx Pharmaceutical Inc. (RARE) Presents at UBS Global Biopharma Conference 2026 TranscriptSeeking Alpha • Tuesday
Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy LaunchesMarketBeat • Tuesday
Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)GlobeNewsWire • 11/06/26
Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 11/03/26
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027GlobeNewsWire • 11/03/26
Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate UpdateGlobeNewsWire • 10/27/26
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/27/26
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a WeekZacks Investment Research • 10/15/26
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?Zacks Investment Research • 10/14/26
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 MillionGlobeNewsWire • 10/14/26
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost CashZacks Investment Research • 10/08/26
Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 millionProactive Investors • 10/07/26
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 MillionGlobeNewsWire • 10/07/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREGlobeNewsWire • 10/06/26
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA ValidationZacks Investment Research • 10/05/26
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)GlobeNewsWire • 10/02/26
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene TherapyZacks Investment Research • 09/18/26
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?Zacks Investment Research • 09/18/26